keyword
https://read.qxmd.com/read/38646859/evaluation-of-clinical-response-and-prognostic-factors-in-canine-multicentric-lymphoma-treated-with-first-rescue-therapy
#21
JOURNAL ARTICLE
John E Blaxill, Peter F Bennett
Despite an initial strong response in most dogs with multicentric lymphoma treated with chemotherapy, relapse remains common. There is no clearly superior first rescue protocol described either for resistant or relapsed canine multicentric lymphoma. The objectives of this study were to assess clinical response and outcomes for canine multicentric lymphoma treated with first rescue protocols. The secondary objective was to assess prognostic variables for dogs undergoing these protocols. This was a bi-institutional retrospective cohort study...
April 22, 2024: Veterinary and Comparative Oncology
https://read.qxmd.com/read/38646708/immune-related-adverse-effects-recognition-and-initiation-of-appropriate-treatment-in-cancer-patients-on-immunotherapy
#22
JOURNAL ARTICLE
Riley Mohr, Anna Howard, Melanie Townsend
PURPOSE: Delayed or improper identification of immune-related adverse events (IRAEs) during cancer treatment can impact time to receive proper treatment. This study describes rates of IRAE recognition and appropriate treatment in adult patients with cancer at a community teaching hospital. METHODS: This single-center, retrospective, cohort study evaluated rates of proper IRAE treatment in conjunction with National Comprehensive Cancer Network (NCCN) guidelines. Secondary outcomes included time from presentation to IRAE diagnosis and hospital readmissions/repeat emergency department (ED) visits following initial admission for IRAE...
April 22, 2024: Journal of Oncology Pharmacy Practice
https://read.qxmd.com/read/38646648/theranostics-a-sure-cure-for-cancer-after-100-years
#23
REVIEW
Yangmeihui Song, Jianhua Zou, E Alejandro Castellanos, Naomi Matsuura, John A Ronald, Adam Shuhendler, Wolfgang A Weber, Assaf A Gilad, Cristina Müller, Timothy H Witney, Xiaoyuan Chen
Cancer has remained a formidable challenge in medicine and has claimed an enormous number of lives worldwide. Theranostics, combining diagnostic methods with personalized therapeutic approaches, shows huge potential to advance the battle against cancer. This review aims to provide an overview of theranostics in oncology: exploring its history, current advances, challenges, and prospects. We present the fundamental evolution of theranostics from radiotherapeutics, cellular therapeutics, and nanotherapeutics, showcasing critical milestones in the last decade...
2024: Theranostics
https://read.qxmd.com/read/38646501/progress-in-cancer-research-on-the-regulator-of-phagocytosis-cd47-which-determines-the-fate-of-tumor-cells-review
#24
REVIEW
Fan Wu, Hongyuan Pang, Fan Li, Mengqing Hua, Chuanwang Song, Jie Tang
Cluster of differentiation 47 (CD47) is a transmembrane protein that is widely and moderately expressed on the surface of various cells and can have an essential role in mediating cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis and other related responses by binding to its ligands, integrins, thrombospondin-1 and signal regulatory protein α. The poor prognosis of cancer patients is closely associated with high expression of CD47 in glioblastoma, ovarian cancer, breast cancer, bladder cancer, colon cancer and hepatocellular carcinoma...
June 2024: Oncology Letters
https://read.qxmd.com/read/38646500/tumor%C3%A2-suppressive-effects-of-smad%C3%A2-ubiquitination-regulator-2-in-papillary-thyroid-carcinoma
#25
JOURNAL ARTICLE
Guirong Luo, Liting Zhang, Lihong Zhang, Wenyi Wu, Jianqing Lin, Haihong Shi, Yihuang Yu, Weigang Qiu, Jinyan Chen, Hansen Ding, Xinyao Chen
Smad-ubiquitination regulator 2 (SMURF2) functions as a homolog of E6AP carboxyl terminus-type E3 ubiquitin ligase to regulate cell cycle progression and tumor growth factor expression. SMURF2 has been revealed to function as a tumor suppressor in a number of cancers; however, its function in papillary thyroid carcinoma (PTC) remains largely unknown. Therefore, the aim of the present study was to investigate the function of SMURF2 in PTC. Reverse transcription-quantitative PCR and western blotting were used to detect cellular expression of SMURF2 in vitro ...
June 2024: Oncology Letters
https://read.qxmd.com/read/38646499/advances-in-molecular-mechanisms-of-inflammatory-bowel-disease%C3%A2-associated-colorectal-cancer-review
#26
REVIEW
Zhi Wang, Yu Chang, Haibo Sun, Yuqin Li, Tongyu Tang
The link between inflammation and cancer is well documented and colonic inflammation caused by inflammatory bowel disease (IBD) is thought to be a high-risk factor for the development of colorectal cancer (CRC). The complex crosstalk between epithelial and inflammatory cells is thought to underlie the progression from inflammation to cancer. The present review collates and summarises recent advances in the understanding of the pathogenesis of IBD-associated CRC (IBD-CRC), including the oncogenic mechanisms of the main inflammatory signalling pathways and genetic alterations induced by oxidative stress during colonic inflammation, and discusses the crosstalk between the tumour microenvironment, intestinal flora and host immune factors during inflammatory oncogenesis in colitis-associated CRC...
June 2024: Oncology Letters
https://read.qxmd.com/read/38646498/metastatic-breast-cancer-with-double-heterozygosity-for-the-brca1-and-brca2-genes-responding-to-olaparib-a-case-report
#27
Bin Shao, Lijun Di
Olaparib was the first poly ADP-ribose polymerase inhibitor approved for patients with cancer with mutations in either BRCA1 or BRCA2 in China. To the best of our knowledge, however, no study has described the efficacy of olaparib for patients with breast cancer with double mutations in BRCA1 and BRCA2 . The present case report describes a patient with breast cancer with deleterious germline mutations in both BRCA1 and BRCA2 . The 56-year-old patient with multiple metastatic breast cancer underwent breast cancer resection with 12 years interval between removal of the left and right breast...
June 2024: Oncology Letters
https://read.qxmd.com/read/38646493/non%C3%A2-coding-rna-a-promising-diagnostic-biomarker-and-therapeutic-target-for-esophageal-squamous-cell-carcinoma-review
#28
REVIEW
Longze Zhang, Yanyang Wang, Jianmei Gao, Xue Zhou, Minglei Huang, Xianyao Wang, Zhixu He
Esophageal cancer (EC) is a common form of malignant tumor in the digestive system that is classified into two types: Esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinoma. ESCC is known for its early onset of symptoms, which can be difficult to identify, as well as its rapid progression and tendency to develop drug resistance to chemotherapy and radiotherapy. These factors contribute to the high incidence of disease and low cure rate. Therefore, a diagnostic biomarker and therapeutic target need to be identified for ESCC...
June 2024: Oncology Letters
https://read.qxmd.com/read/38646492/clinical-prognostic-significance-of-xeroderma-pigmentosum-group-c-and-ifn%C3%A2-%C3%AE-in-non%C3%A2-small-cell-lung-cancer
#29
JOURNAL ARTICLE
Yongming Wang, Weiyu Wang, Huaijie Wang, Liya Qin, Meijia Zhang, Yong Zhang, Yubing Wang, Changcheng Hao, Meihua Qu, Gongchao Wang
Lung cancer is the most common cancer in the world due to its high incidence and recurrence. Genetic instability is one of the main factors leading to its occurrence, development and poor prognosis. Decreased xeroderma pigmentosum group C (XPC) expression notably enhances the stem cell properties of lung cancer cells and increases their proliferation and migration. Additionally, patients with lung cancer and low XPC expression had a poor prognosis. The purpose of the present study was to analyze the effect of XPC and IFN-γ on the clinical prognosis of patients with non-small cell lung cancer (NSCLC)...
June 2024: Oncology Letters
https://read.qxmd.com/read/38646491/clinical-significance-of-the-cxcl8-cxcr1-r2-signalling-axis-in-patients-with-invasive-breast-cancer
#30
JOURNAL ARTICLE
Sebastian Stępień, Marta Smycz-Kubańska, Celina Kruszniewska-Rajs, Joanna Magdalena Gola, Jacek Kabut, Paweł Olczyk, Aleksandra Mielczarek-Palacz
The C-X-C motif chemokine ligand 8 (CXCL8)-C-X-C chemokine receptor (CXCR)1/2 signalling axis is among numerous mechanisms which stimulate the immune system to defend against tumour growth and influence the tumour microenvironment to promote tumour growth. This pathway plays an important role in the development of a number of cancers including breast cancer (BC). The aim of the present study was to analyse the levels of the chemokine CXCL8 and its receptors, CXCR1 and CXCR2, in the serum of female patients with invasive BC and to assess the expression of these parameters at the mRNA level, considering molecular subtypes and degrees of cancer malignancy...
June 2024: Oncology Letters
https://read.qxmd.com/read/38646445/window-of-opportunity-with-pd1-blockade-before-chemoradiotherapy-for-an-advanced-stage-clear-cell-carcinoma-of-the-cervix
#31
Marie-Gabrielle Courtès, Melpomeni Kountouri, Wenwen Wang, Jean-Christophe Tille, Patrick Petignat, Manuela Undurraga, S Intidhar Labidi-Galy
Clear cell carcinoma is a rare and very aggressive subset of cervical cancer, with poor outcome if diagnosed at advanced stage. There are few data available on the optimal management of this histotype, and treatment recommendations that include surgery and chemoradiotherapy, are essentially based on those for squamous cell carcinoma. Here we report the case of a young patient newly diagnosed with advanced stage (FIGO IIB) clear cell carcinoma of the uterine cervix who received a window of opportunity one injection of nivolumab followed by standard chemoradiotherapy...
June 2024: Gynecologic Oncology Reports
https://read.qxmd.com/read/38646444/case-report-low-risk-hpv-associated-verruco-papillary-squamous-cell-carcinoma-of-the-cervix
#32
Olivia Nicolais, Mackenzie Cummings, Tommy R Buchanan
•Cervical cancer plays a large role in morbidity and mortality for gynecologic cancer.•Most cases are involved with high-risk HPV, rare cases of low-risk HPV associated cancer exists.•Low risk HPV associated cervical cancers have increased difficulty in diagnosis.•No distinction exists in treatment between low and high risk HPV associated cervical cancer.
June 2024: Gynecologic Oncology Reports
https://read.qxmd.com/read/38646441/profiling-of-serum-metabolome-of-breast-cancer-multi-cancer-features-discriminate-between-healthy-women-and-patients-with-breast-cancer
#33
JOURNAL ARTICLE
Katarzyna Mrowiec, Julia Debik, Karol Jelonek, Agata Kurczyk, Lucyna Ponge, Agata Wilk, Marcela Krzempek, Guro F Giskeødegård, Tone F Bathen, Piotr Widłak
INTRODUCTION: The progression of solid cancers is manifested at the systemic level as molecular changes in the metabolome of body fluids, an emerging source of cancer biomarkers. METHODS: We analyzed quantitatively the serum metabolite profile using high-resolution mass spectrometry. Metabolic profiles were compared between breast cancer patients (n=112) and two groups of healthy women (from Poland and Norway; n=95 and n=112, respectively) with similar age distributions...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38646440/macrophage-colony-stimulating-factor-and-its-role-in-the-tumor-microenvironment-novel-therapeutic-avenues-and-mechanistic-insights
#34
REVIEW
Li Yi, Yihan Gai, Zhuo Chen, Kecan Tian, Pengfei Liu, Hongrui Liang, Xinyu Xu, Qiuyi Peng, Xiaoqing Luo
The tumor microenvironment is a complex ecosystem where various cellular and molecular interactions shape the course of cancer progression. Macrophage colony-stimulating factor (M-CSF) plays a pivotal role in this context. This study delves into the biological properties and functions of M-CSF in regulating tumor-associated macrophages (TAMs) and its role in modulating host immune responses. Through the specific binding to its receptor colony-stimulating factor 1 receptor (CSF-1R), M-CSF orchestrates a cascade of downstream signaling pathways to modulate macrophage activation, polarization, and proliferation...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38646439/diversity-of-extracellular-hsp70-in-cancer-advancing-from-a-molecular-biomarker-to-a-novel-therapeutic-target
#35
REVIEW
Binbin Hu, Guihong Liu, Kejia Zhao, Gao Zhang
Heat shock protein 70 (HSP70) is a highly conserved protein functioning as a "molecular chaperone", which is integral to protein folding and maturation. In addition to its high expression within cells upon stressful challenges, HSP70 can be translocated to the cell membrane or released from cells in free form or within extracellular vesicles (EVs). Such trafficking of HSP70 is also present in cancer cells, as HSP70 is overexpressed in various types of patient samples across a range of common malignancies, signifying that extracellular HSP70 (eHSP70) can serve as a tumor biomarker...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38646437/editorial-overcoming-obstacles-of-cancer-immunotherapy-the-important-role-of-emerging-nanomedicine
#36
EDITORIAL
Aimin Jiang, Wangxiao He, Yu Yao
No abstract text is available yet for this article.
2024: Frontiers in Oncology
https://read.qxmd.com/read/38646436/paratesticular-metastasis-from-colorectal-adenocarcinoma-presenting-as-hydrocele-a-rare-case-report-and-literature-review
#37
XiaoJun Huang, KeLi Xu, Yin Zhao, MinHui Chen, ZheYang Li
Colorectal cancer, with the liver being the most common site of distant metastasis, followed by the lungs and bones. Although reports of metastasis to the testis exist, paratesticular metastasis is extremely rare. A 37-year-old male presented with scrotal swelling. Ultrasound revealed hydrocele of the tunica vaginalis. The patient underwent routine surgical treatment, and postoperative pathology of the tunica vaginalis indicated adenocarcinoma of gastrointestinal origin. Colonoscopic biopsy confirmed adenocarcinoma of the sigmoid colon...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38646434/case-report-unusual-breast-cancer-metastasis-manifesting-as-a-scalp-lesion-in-a-patient-with-invasive-lobular-carcinoma
#38
Nam Hee Koh, Ha Yeun Oh
Breast cancer is the most prevalent cancer in women globally, often leading to distant metastasis in the lung, liver, or bones. Cutaneous metastasis represents an uncommon pattern in breast cancer, but when observed, it tends to manifest in the thorax and upper abdomen, primarily due to lymph node involvement. Therefore, occurrences of cutaneous metastasis on the scalp and extremities are infrequent. Moreover, invasive lobular carcinoma metastasizing to remote skin is rare among the breast cancer. This report presents a case of cutaneous metastasis of invasive lobular carcinoma to the scalp in a patient treated for breast cancer six years ago, with no signs of local recurrence or metastasis to other organs...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38646432/tace-assisted-multi-image-guided-radiofrequency-ablation-for-the-treatment-of-single-hepatocellular-carcinoma-%C3%A2-5%C3%A2-cm-a-retrospective-study
#39
JOURNAL ARTICLE
Yong Xie, Tianshi Lyu, Li Song, Xiaoqiang Tong, Jian Wang, Yinghua Zou
BACKGROUND/OBJECTIVE: Treatment of hepatocellular carcinoma (HCC) with ablation alone often results in high rates of recurrence and metastasis, reaching up to 25.9% within two years. Therefore, this study aimed to examine the efficacy and safety of transarterial chemoembolization (TACE)-assisted multi-image guided radiofrequency ablation (RFA) for the treatment of stage Ia HCC according to the China liver cancer staging (CNLC). METHODS: This study enrolled and analyzed a total of 118 patients diagnosed with HCC, each with a single nodular lesion no larger than 5 cm, who received TACE-RFA as first-line therapy between February 1, 2014, and December 31, 2021...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38646430/oral-cancer-in-young-adults-should-we-approach-these-patients-differently
#40
JOURNAL ARTICLE
Mateusz Szewczyk, Jakub Pazdrowski, Paweł Golusiński, Barbara Więckowska, Wojciech Golusiński
OBJECTIVE: The influence of age on treatment outcomes in oral cancer is unclear. We aimed to determine the prevalence of oral cancer in adults under age 45 and to compare treatment outcomes by age. METHODS: Retrospective study of 284 patients treated for oral cancer from 2010 to 2021. The primary analysis involved the full cohort stratified by age (< vs. ≥ 45y). The second analysis included all patients under age 45 (n=44) matched 1:1 by sex and stage to older patients (age 55-70)...
2024: Frontiers in Oncology
keyword
keyword
7827
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.